Brevinor 1/28 (ethinyloestradiol 35 mcg with norethisterone 1 mg): Stock issue
Pfizer, the supplier, has advised PHARMAC that the combined oral contraceptive Brevinor 1/28 will run out of stock in August.
Looking for information about Brevinor 28?
Brevinor 28 is a different oral contraceptive from Brevinor 1/28. It has a lower progestogen strength. Brevinor 28 is an alternative to Norimin.
On this page:
- Supply status for Brevinor 1/28
- Information for people taking Brevinor 1/28
- Information for prescribers
- Information for pharmacists
Pfizer advised that stock of Brevinor 1/28 has run out. They are expecting more stock to arrive in New Zealand by mid-October 2020.
Pfizer has been unable to source an alternative brand that is chemically equivalent.
There are on-going global constraints on all ethinyloestradiol and norethisterone products. We have previously seen the impact of this with Norimin.
We recognise this short supply situation may be disruptive for some people and we apologise for this. We will continue to update this web page as information becomes available.
If you are currently taking Brevinor 1/28 and you need a new prescription, you will need to talk to your prescriber about what alternative contraceptive options that are best for you.
We recognise this short supply situation may be disruptive for some people and we thank you for your understanding.
Your health professional will provide you with advice on the alternative types of contraception that are available, including discussing with you:
- what alternative form of contraception would work best for you
- how to maintain effective contraception when switching between brands or types of contraception
- the 7-day rule when switching between brands
The supplier, Pfizer, has a supply issue with Brevinor 1/28 and has been unable to source an alternative brand that is chemically equivalent. This means that people you treat who are taking Brevinor 1/28, and who need more medicine, will need to see you to get a new prescription for an alternative.
Alternative funded combined oral contraceptives are listed on the Pharmaceutical Schedule.
You will need to be prepared to discuss:
- alternative forms of contraception
- maintaining effective contraception when switching between brands or between different contraceptives
- following the 7-day rule when switching between brands.
BPAC provides guidance for health professionals about other funded contraceptive options.
The supplier, Pfizer, has a supply issue with Brevinor 1/28 (pharmacode 303542) and has been unable to source an alternative brand that is chemically equivalent. This means that people taking Brevinor 1/28 who need more medicine will need to see their prescriber to discuss what other alternatives are available.
We recommend you discuss:
- the need to go back to their prescriber for a new prescription
- how to maintain effective contraception when switching between brands or between different contraceptives
- following the 7-day rule when switching between brands
Last updated: 2 September 2020